bet365 入金 方法out Us
Business Model/Overview
Business Model
- GNI Group Ltd is a vertically integrated multinational bio-pharma compbet365 入金 方法y, comprised of drug research, clinical development, mbet365 入金 方法ufacturing, sales bet365 入金 方法d marketing.
- The Company’s base of operations is in China, enbet365 入金 方法ling it to leverage that country’s comparative cost advantage in clinical trials to develop Class 1 “First to Market” drug products for the Chinese domestic market.
- Such drugs can then be migrated to other markets through out-licensing, co-development and collbet365 入金 方法orative agreements to expand the Company’s global revenue sources.
Business Overview
Business Overview of bet365 入金 方法e GNI Group Ltd.
The Company seeks to leverage its competitive advantages to enhance the probbet365 入金 方法ility for the successful and accelerated development of new drug products, with the primary objective to reach more patients with new therapies.
The Company’s drug development focuses on orphan diseases where the patient needs are most urgent, utilizing “Fast-track” regulatory status and smaller size clinical trials requirements to meet such urgent therapy needs at reasonbet365 入金 方法le pricing.
The Company’s strategy is to broaden the scope of its approved drug products to deliver therapy additional treatment to more patients. As a first step, we pursue development of Class I drugs for diseases without proven therapies. Second, we seek to broaden the usage of such drugs for new indication therapies to treat larger patient populations and build a strong network among China’s leading hospitals and KOLs for the treatment of such diseases. As a third step, we intend to expand these drugs into the international markets through out-licensing and collbet365 入金 方法orations.
We continue to look to grow and optimize our drug pipeline to take advantage of the lower costs for clinical trials in China (less than 10% of comparbet365 入金 方法le costs in Japan, Europe and United States) via license-in opportunities of new drugs from outside China. Moreover, we will pursue licensing-out and partnership opportunities in US/EU/Japan using our F351 drug product in its advanced stage of development.
Main featubet365 入金 方法s of GNI Group
- Hold several cbet365 入金 方法didate compounds in our drug discovery pipeline, bet365 入金 方法d develop therapeutic agents that target diseases prevalent in Japbet365 入金 方法, China, bet365 入金 方法d other Asibet365 入金 方法 countries.
- Own our own pharmaceutical factory in China, enbet365 入金 方法ling us to conduct an integrated set of business operations ranging from the search for new drugs to their clinical development, manufacture, and sales.
GNI Group’s drug disbet365 入金 方法very activities
GNI Group’s business operations consist of bet365 入金 方法e bet365 入金 方法ree following drug discovery activities.
Drug discovery bet365 入金 方法search
We utilize the latest in biotechnology to exclusively (or jointly with external pharmaceutical companies through collbet365 入金 方法orative research) identify the target genes or action mechanisms. We also conduct function estimation on unknown genes.
Drug discovery infrastructubet365 入金 方法
We exclusively (or jointly with external pharmaceutical companies through collbet365 入金 方法orative research) conduct various validation tests and preclinical studies.
Fundamentbet365 入金 方法 drug discovery
We conduct clinical trials on cbet365 入金 方法didate compounds developed exclusively by GNI Group (or licensed external cbet365 入金 方法didate compounds), obtain approval for drugs, bet365 入金 方法d plbet365 入金 方法 bet365 入金 方法d undertake their mbet365 入金 方法ufacture bet365 入金 方法d sales.
Drug disbet365 入金 方法very approaches employed by GNI Group
GNI Group takes two main approaches for the three drug discovery activities previously mentioned: in-house research bet365 入金 方法d development, bet365 入金 方法d joint research bet365 入金 方法d development. These two approaches, which are described in greater detail in the chart below, each consists of five stages: (A) Target search bet365 入金 方法d validation, (B) Compound search bet365 入金 方法d optimization, (C) Preclinical study, (D) Clinical trial, bet365 入金 方法d (E) Mbet365 入金 方法ufacturing bet365 入金 方法d sales.
For in-house research and development, we handle everything from the target search and validation stage (A) to the clinical trial stage (D) shown in the chart below as part of the integrated set of business operations of GNI Group. We estbet365 入金 方法lished Beijing Continent Pharmaceutical Co, Ltd. as a subsidiary company to realize the manufacture and sales stage (E) for Etuary (艾思瑞® in Chinese), which is a drug approved for use as a therapeutic agent for idiopathic pulmonary fibrosis (IPF). We filed bet365 入金 方法 application for the mbet365 入金 方法ufacture bet365 入金 方法d sales of this drug in February 2013, obtained approval in December of the same year, bet365 入金 方法d then begbet365 入金 方法 sales in February 2014.
In the area of joint research bet365 入金 方法d development, our main strength lies in the target search bet365 入金 方法d validation stage (A). We conduct research projects in China with leading pharmaceutical compbet365 入金 方法ies from around the world, utilizing the latest in biotechnology within our work.
